Is Your DNA Data Safe in Blackstone’s Hands?
By Matthew Ponsford,
Neo.Life
| 01. 28. 2021
We’re beginning to get a picture of the people who might have a goldmine in their genome.
The paradox of treating your own DNA as a commodity is that you’d actually be lucky if you’ve got a rare, poorly understood genetic disease, as those troublesome stretches of DNA may be the most valuable for medical research, explains Dennis Grishin, the cofounder of Nebula Genomics, a California company offering whole genome sequencing. You’d be luckier still if you have genetic patterns that would usually cause you to become ill with a disease like this, and yet appear completely healthy. That’s one variety of in-demand DNA: genomes belonging to people that Grishin calls “natural knockouts,” meaning genetic variations in the disease-associated genes in their genomes somehow save them from falling ill.
“There are people who have ‘broken genes’ and actually should be severely sick. But they are not sick for some reason, and we don’t really understand why,” Grishin says. “So there is some kind of compensatory mechanism going on that prevents people from getting sick.”
Sequencing the genomic data of these...
Related Articles
By Diaa Hadid and Shweta Desai, NPR | 01.29.2026
MUMBRA, India — The afternoon sun shines on the woman in a commuter-town café, highlighting her almond-shaped eyes and pale skin, a look often sought after by couples who need an egg to have a baby.
"I have good eggs,"...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Staff, ScienceDaily | 01.05.2026
Scientists at UNSW Sydney have developed a new form of CRISPR technology that could make gene therapy safer while also resolving a decades-long debate about how genes are switched off. The research shows that small chemical markers attached to DNA
...
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...